Oppenheimer Initiates Prothena With Outperform
Analysts at Oppenheimer initiated coverage on shares of Prothena (NASDAQ: PRTA) with a Outperform rating.
The target price for Prothena is set to $40.
Prothena shares have dropped 1.50% over the past 52 weeks, while the S&P 500 index has surged 16.93% in the same period.
Prothena's shares fell 0.71% to close at $20.94 yesterday.
Latest Ratings for PRTA
|May 2016||Barclays||Initiates Coverage on||Overweight|
|Jan 2016||Credit Suisse||Initiates Coverage on||Outperform|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.